Weekly Life Science News Round Up: 16th – 20th May
A round-up of the latest news from the Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 16th-20th May.
Finding treatment options for skin cancer may become easier with the launch of a new test by Labcorp, a leading global life sciences company.
At a dedication today of the new Jeffrey Leiden Center for Cell and Genetic Therapies in Boston’s Seaport, Vertex Pharmaceuticals Incorporated announced plans to build another 344,000 square foot facility in the Seaport to support the company’s continued rapid growth.
AbbVie and Cugene Inc. announce an exclusive worldwide license option agreement for CUG252, a potential best-in-class Treg-selective IL-2 mutein, as well as other novel IL-2 muteins, for the potential treatment of autoimmune and inflammatory diseases.
BenevolentAI announces that AstraZeneca has selected an additional novel target for idiopathic pulmonary fibrosis (IPF) for its drug development portfolio, resulting in a milestone payment to BenevolentAI.
BeiGene announce the opening of a new regional office in Basel, Switzerland, which will service as a hub for the company’s operations in the region.
A study into how well additional doses of the Covid-19 vaccine protects immunosuppressed people is set to be extended to include young people following a recent funding extension.
Moderna continues to highlight investments in the expansion of the utility of the mRNA platform, characterisation of the Company’s vaccines, biodistribution of vaccines, and using clinical data to predict vaccine dosing.
The PPD clinical research business of Thermo Fisher Scientific has been recognized for excellence in the 2022 CRO Leadership Awards. This is the 11th consecutive year the business has been honored through this award program.
The Janssen Pharmaceutical Companies of Johnson & Johnson announce the launch of Depression Looks Like Me, a campaign aimed at normalizing the conversation about depression in the LGBTQ+ community and empowering people to seek the mental health care they may need.
Gilead Sciences, Inc. was officially recognized as the number one philanthropic funder of HIV-related programs in a new tracking report released by Funders Concerned About AIDS (FCAA). The report is released annually and is widely regarded as the most comprehensive study of its kind.
Beckley Psytech and Empatica, Inc. announce that the companies have entered into a strategic partnership to support the collection and analysis of behavioural and physiological data in Beckley Psytech’s future clinical trials.
Evotec SE and Sernova Corp. announce a partnership in the field of diabetes. Both companies will leverage their respective strengths to develop an implantable iPSC-based beta cell replacement therapy for the treatment of insulin-dependent diabetes, including type 1 and 2.
Sosei Group Corporation and New York City-based Kallyope have entered a strategic research collaboration to identify and validate novel G protein-coupled receptor (GPCR) targets with a goal of creating new drug discovery programs in the area of gastrointestinal diseases.
DelSiTech Ltd. and Anticancer Bioscience Ltd. announce a notable collaboration pertaining to the development of silica-based long-acting controlled release treatments in oncology.
Shionogi & Co., Ltd. and F2G Ltd. announce that they have entered a strategic collaboration to develop and commercialize the new antifungal agent olorofim for invasive fungal infections in Europe and Asia.
See more of the latest Life Science news on PharmiWeb.com.